Pharmaceutical News

RSS

Most Americans still believe outdated antibiotic guidance, study finds

"Always finish your antibiotics" is no longer considered medical best practice for all conditions.

13 Aug 2026

SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the introduction of CHO.SET® 2.0. The expanded library of novel and patentable synthetic promoters is designed to improve protein production in CHO (Chinese Hamster Ovary) cells.

From SynGenSys Ltd. 13 Aug 2026

Pediatric leucovorin use spiked after federal officials touted its benefits for autism

Leucovorin prescriptions for children spiked after federal officials claimed the drug was an effective treatment for autism during a September 2025 press conference, according to a new Michigan Medicine-led study published in The New England Journal of Medicine.

12 Aug 2026

Researchers find unexpected protein regulator of leukemia drug sensitivity

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

12 Aug 2026

Insilico Medicine nominates powerful oral drug candidate for the management of heart risks

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inhibitor of lipoprotein(a), or Lp(a), as a preclinical candidate (PCC) for the management of cardiovascular risks.

12 Aug 2026

Modern blood thinners slow cognitive decline in Alzheimer's patients

People with both atrial fibrillation and Alzheimer's disease who are treated with modern NOAC blood-thinning medicines may experience a slower rate of cognitive decline.

12 Aug 2026

Dexamethasone calms lung inflammation without weakening core immune responses

Researchers from Trinity College Dublin and St. James's Hospital have shown that dexamethasone, a commonly prescribed anti-inflammatory steroid, can reduce harmful inflammation triggered by Mycobacterium avium without weakening the ability of human immune cells to control the infection.

11 Aug 2026

New study identifies key pathway for delivering antisense cancer drugs

Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer.

11 Aug 2026

Semaglutide slows blood protein signature linked to future dementia risk

A post hoc analysis of 2,970 older SELECT participants found that semaglutide slowed worsening of a 25-protein blood signature that predicts future dementia risk. Over 104 weeks, semaglutide produced larger effects on modeled 5-year than 20-year dementia risk, but whether these biomarker changes translate into less cognitive decline or dementia remains unknown.

10 Aug 2026

Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes

In a US cohort of 52,971 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide initiation was associated with a lower one-year risk of major adverse cardiovascular events than sitagliptin. The benefit was driven mainly by lower myocardial infarction and all-cause mortality hazards, although the authors cautioned that mortality findings may be influenced by residual confounding.

10 Aug 2026

Nicotine gum may make smokeless tobacco withdrawal easier to manage

A randomized trial found that 2 mg nicotine gum controlled craving, anxiety, and sleep problems more effectively than behavioral counselling during smokeless tobacco cessation. Although abstinence rates were numerically higher with nicotine gum, the differences were not statistically significant, highlighting the need for larger studies.

6 Aug 2026

GLP-1 drug tirzepatide associated with lower risk of major cardiovascular events

Adding the GLP-1 receptor agonist drug tirzepatide (marketed as Mounjaro) to standard care for patients with type 2 diabetes and heart disease is associated with a lower risk of a major cardiovascular event, such as a heart attack or stroke, finds a study published by The BMJ today.

5 Aug 2026

Long-acting HIV prevention tools could help close the gap before a vaccine arrives

A review of non-vaccine HIV interventions highlights the strong preventive effects of long-acting PrEP, sustained ART, U=U, vertical transmission programs, and voluntary medical male circumcision. Gene editing and multispecific antibodies may expand future options, but safety, cost, access, adherence, and implementation barriers remain.

5 Aug 2026

Medical cannabis compound alleviates nightmares associated with PTSD

Nightmares are among the most agonizing symptoms of post-traumatic stress disorder (PTSD) – a condition that can develop after exposure to severe traumatic experiences, such as disasters, serious accidents, acts of violence, or wartime experiences. Individuals affected relive the events intensely at night, as if they were real, time and time again.

5 Aug 2026

Mouse study shows how liraglutide briefly rewires gut bacterial communities

Researchers treated male high-fat-fed mice with liraglutide for 14 days, then tracked fecal bacterial communities after a 7-day washout using 16S rRNA sequencing. Liraglutide shifted the microbiome toward Lactobacillus- and Leptogranulimonas-related taxa while reducing several fermentative taxa, but most changes moved back toward baseline after treatment stopped.

4 Aug 2026

$GLP-1 therapy may help reduce fracture risk among adults with type 2 diabetes$

GLP-1 therapy may help reduce fracture risk among adults with type 2 diabetes

New research by UCLA Health found GLP-1 medications may reduce the risk of serious fractures for adults with type 2 diabetes.

4 Aug 2026

Tadalafil may increase glaucoma risk in men with enlarged prostates

An erectile dysfunction drug that is also used to treat symptoms like sudden urgency and frequency, which are associated with an enlarged prostate in men, may heighten the risk of the serious eye condition, glaucoma, finds a large comparative study published online in the British Journal of Ophthalmology.

4 Aug 2026

Food may taste different on GLP-1 drugs, but taste may not be the reason

The review suggests that patient-reported “taste changes” during GLP-1RA treatment may reflect reduced food enjoyment and motivation rather than consistent impairment of basic taste. The authors propose a sensory-liking-wanting framework while emphasizing that current human evidence remains heterogeneous and largely indirect.

4 Aug 2026

'Me-too' drugs drive increased spending through higher prescribing

A long-running debate over prescription drug costs has centered on whether drug manufacturers are better rewarded for truly innovative medicines or so-called "me-too" drugs that may offer only incremental improvements over existing treatments but still command high prices.

3 Aug 2026

Ten-million-person study links semaglutide to lower COVID-19 mortality

Researchers analyzing claims from more than 10.1 million commercial insurance and Medicare Advantage enrollees found that semaglutide use was associated with a 49% lower adjusted hazard of COVID-19-related death. The observational findings corroborate earlier SELECT trial results but do not establish causation, making further prospective research essential.

30 Jul 2026